HI
RXRX icon

Harbour Investments’s Recursion Pharmaceuticals RXRX Stock Holding History

Harbour Investments’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.21K Buy
1,369
+73
+6% +$282 ﹤0.01% 3651
2025
Q4 		$5.3K Hold
1,296
– – ﹤0.01% 2996
2025
Q3 		$6.32K Hold
1,296
– – ﹤0.01% 2892
2025
Q2 		$6.56K Sell
1,296
-100
-7% -$491 ﹤0.01% 2763
2025
Q1 		$7.38K Buy
1,396
+396
+40% +$2.89K ﹤0.01% 2661
2024
Q4 		$6.76K Hold
1,000
– – ﹤0.01% 2618
2024
Q3 		$6.59K Buy
+1,000
New +$7.17K ﹤0.01% 2530

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Harbour Investments's RXRX Position: Q1 2026 in Review

Harbour Investments increased its Recursion Pharmaceuticals (RXRX) stake by 5.6% in Q1 2026, buying an estimated $282 and bringing the position to 1,369 shares worth $4.21K. The position accounts for ﹤0.01% of the portfolio, ranked #3651.

Harbour Investments first reported a position in RXRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $7.38K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Harbour Investments held 1,369 shares of Recursion Pharmaceuticals worth $4.21K as of Q1 2026.
  • Harbour Investments bought 73 Recursion Pharmaceuticals shares in Q1 2026, an estimated $282.
  • Recursion Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #3651 holding.
  • Harbour Investments first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Harbour Investments's Recursion Pharmaceuticals position peaked at $7.38K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.